The Molecular Genetics Program at the Masonic Medical Research Laboratory has assembled a team of investigators capable of streamlining the approach to genetic screening and subsequent functional in vitro analysis of ion channel mutations linked to inherited cardiac arrhythmia and conduction disease. We are certified as a CLIA/CLEP-approved clinical laboratory by the New York State Department of Health.
We invite your participation and collaboration in these projects. We are particularly interested in individuals, or preferably, large families with any of the following:
» Brugada Syndrome
Spontaneous Brugada ECG phenotype
Brugada phenotype unmasked or induced by sodium channel blockers, hormonal imbalances
pheochromocytoma,antidepressant or other drugs, hyponatremia or other electrolyte imbalances,
alcohol, vagotonic agents or vagal, maneuvers (including full stomach).
» Familial Atrial Fibrillation
» Catecholamine-sensitive VT
» Non-ischemia-related VT/VF occurring in young individuals
» Post-MI QT prolongation and Torsade de Pointes
» Progressive Conduction Disease
» Sudden death in infants and children (including SIDS)
» Acquired Long QT Syndrome (Congenital LQTS cases should be referred to familion or other commercial testing facilities)
» Short QT Syndrome
Please do not hesitate to contact us regarding these or other familial arrhythmic syndromes. Should a new mutation or gene be uncovered as a result of genetic screen of the DNA samples provided, the submitting physician will be included as a co-author.
Blood Collection and Delivery: Instruction for collection and delivery of blood can be found at Blood Collection and Delivery Instructions.
Informed Consent Forms: We will require you to obtain informed consent from each patient selected for participation in the study. Informed consent forms can be found at Informed Consent Forms 1 and 2 .Patient must sign both in order for us to proceed with both Clinical Diagnosis and Research Protocols.
Clinical History and ECGs: You will also be required to fill out a clinical history form, which can be found at Clinical History Form and provide us with ECGs supporting the diagnosis.
An authorization number for submission of blood/DNA will be issued once the clinical data are reviewed.Blood/DNA will not be accepted for processing without an authorization number.
Contact Information: Please address all inquiries to genetics@mmrl.edu or Tel : 315-735-2217 ext:119
22.6.10
LONDON SCHOOL of HYGIENE & TROPICAL MEDICINE
http://www.lshtm.ac.uk/prospectus/short
ON-LINE short courses:
TRAVEL MEDICINE $300
EPIDEMIOLOGY: $100
ON-LINE short courses:
TRAVEL MEDICINE $300
EPIDEMIOLOGY: $100
15.6.10
FREE HEALTH SAFETY WATCH
www.healthandsafetywatch.com
519-265-3851
Dr Jeff ARAMINI DVM(Guelph) MSc. PhD(Guelph Epidemiology)
Pres/CEO INTELLIGENT HEALTH SOLUTIONS Inc.
HEALTH & SAFETY WATCH Inc.
MONITORS MEDICAL & ENVIRONMENTAL DANGERS in Canadian GEOGRAPHIC AREAS.
FREE
519-265-3851
Dr Jeff ARAMINI DVM(Guelph) MSc. PhD(Guelph Epidemiology)
Pres/CEO INTELLIGENT HEALTH SOLUTIONS Inc.
HEALTH & SAFETY WATCH Inc.
MONITORS MEDICAL & ENVIRONMENTAL DANGERS in Canadian GEOGRAPHIC AREAS.
FREE
5.6.10
PROVENGE (sipuleucel-T) : DENDREON Corp.
ACTIVE CELLULAR IMMUNOTHERAPY)
www.dendreon.com
Dendreon Corporation (Nasdaq: DNDN) announced the presentation of safety data from the integrated analysis of four randomized PROVENGE(R) (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.
"The approval of PROVENGE provides us with an important new, front-line option for men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer," said Simon Hall, M.D., director of the Barbara and Maurice Deane Prostate Health and Research Center at Mount Sinai Medical Center."
Extended life by average 4.1 months at cost of US$93,000 for 3 dose treatment.
Pres./CEO/Dir. Dr.MITCHELL GOLD MD(Rush,Chicago) Urology resident U.Washington.
Med. Informatics expert.
Sr.V-P.Dr.MARK FROLICH BS(YALE-engineering/economics) MD (HARVARD) past Asst.Prof U.Cal.(San Fran)UROLOGICAL ONCOLOGY
www.dendreon.com
Dendreon Corporation (Nasdaq: DNDN) announced the presentation of safety data from the integrated analysis of four randomized PROVENGE(R) (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.
"The approval of PROVENGE provides us with an important new, front-line option for men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer," said Simon Hall, M.D., director of the Barbara and Maurice Deane Prostate Health and Research Center at Mount Sinai Medical Center."
Extended life by average 4.1 months at cost of US$93,000 for 3 dose treatment.
Pres./CEO/Dir. Dr.MITCHELL GOLD MD(Rush,Chicago) Urology resident U.Washington.
Med. Informatics expert.
Sr.V-P.Dr.MARK FROLICH BS(YALE-engineering/economics) MD (HARVARD) past Asst.Prof U.Cal.(San Fran)UROLOGICAL ONCOLOGY
ANNIDIS RHA
ANNIDIS RHA measures RETINAL HEALTH
www.annidis.com see links on ANNIDIS Google.
Invented and made in CANADA.
Developed in OTTAWA at ANNIDIS Health systems Corp. by Dr. BRIAN LEONARD MD(Ottawa 1970) FRCS(C) who did a Fellowship at Philadelphia's WILLS EYE INSTITUTE in RETINOVITREOUS diseases.
Not yet USA approved.
www.annidis.com see links on ANNIDIS Google.
Invented and made in CANADA.
Developed in OTTAWA at ANNIDIS Health systems Corp. by Dr. BRIAN LEONARD MD(Ottawa 1970) FRCS(C) who did a Fellowship at Philadelphia's WILLS EYE INSTITUTE in RETINOVITREOUS diseases.
Not yet USA approved.
Subscribe to:
Posts (Atom)